Dr. Nagourney discusses the development of drug resistance in colon cancer patients that contributed to the failure of the oxaliplatin-based HIPEC PRODIGE 7 Trial

Dr. Nagourney discusses the development of drug resistance in colon cancer patients that contributed to the failure of the oxaliplatin-based HIPEC PRODIGE 7 Trial

Dr. Nagourney discusses the&nbsp;development of drug resistance in colon cancer patients that contributed to the failure of the oxaliplatin-based HIPEC PRODIGE 7 Trial

Drug Resistance in Colon Cancer

“Outliving Cancer” brings a new perspective to the treatment of human malignancy.  Drawing upon years of experience, Dr. Robert Nagourney, Medical oncologist and Laboratory scientist brings his unique insights into the diagnosis, causes and treatments of this disease.  Join Dr. Nagourney as he explores the cellular origins of human cancer and examines better ways to use existing drugs, targeted agents and a growing number of novel combinations to successfully confront a disease that today is the 2nd leading cause of death in America. It is Dr. Nagourney’s intent to provide cancer patients with the tools that they will need to “outlive their cancers”.

Medicine

Health & Fitness

“Outliving Cancer” brings a new perspective to the treatment of human malignancy. Drawing upon years of experience, Dr. Robert Nagourney, Medical oncologist and Laboratory scientist brings his unique insights into the diagnosis, causes and treatments of this disease. Join Dr. Nagourney as he explores the cellular origins of human cancer and examines better ways to use existing drugs, targeted agents and a growing number of novel combinations to successfully confront a disease that today is the 2nd leading cause of death in America. It is Dr. Nagourney’s intent to provide cancer patients with the tools that they will need to “outlive their cancers”.

Share Drug Resistance in Colon Cancer

Sign up to save your podcasts

Drug Resistance in Colon Cancer

Drug Resistance in Colon Cancer